23andMe to delist from Nasdaq, deregister with SEC
Regeneron Pharmaceuticals said earlier this month that it will acquire "substantially all" of 23andMe's assets for $256 million.
You are not logged in so some information on this page has been withheld. To see more, please log in.
Regeneron
since
auto-detected in 340 stories
47 days ago
55 days ago
23andMe sold out of bankruptcy to Regeneron
Drugmaker’s takeover could raise privacy concerns among genetics start-up’s 15mn users
Regeneron Pharmaceuticals to buy 23andMe and its data for $256 million
Regeneron is acquiring "substantially all" of 23andMe's assets for $256 million following a bankruptcy auction.
Regeneron buys 23andMe for $256m after bankruptcy
Sale of genetic testing company raises concerns about privacy of 23andMe’s 15 million customers.
Bankrupt DNA testing firm 23andMe to be purchased for $256m
found
a story from The Guardian ⚠️ › International
Drugmaker Regeneron Pharmaceuticals’ capture of genetic testing firm in bankruptcy auction raises privacy concerns
The drugmaker Regeneron Pharmaceuticals has agreed to buy the genetic testing firm 23…
56 days ago
Regeneron to buy bankrupt DNA testing firm 23andMe for $256 million
Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe Holding for $256 million through a bankruptcy auction, the companies said on Monday.
75 days ago
Stocks making the biggest moves midday: Spotify, Regeneron, Hims & Hers, Pfizer and more
These are the stocks posting the largest moves in midday trading.
page 1 of 1